195 related articles for article (PubMed ID: 38584122)
1. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
Guo L; Zhou G; Huang M; Tang K; Xu J; Chen J
Clin Respir J; 2024 Apr; 18(4):e13748. PubMed ID: 38584122
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.
Nargesi S; Dolatshahi Z; Rezapour A; Alipour V; Souresrafil A; Farabi H; Javadmoosavi SA; Safakhah M; Moradi N
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):543-554. PubMed ID: 34846235
[TBL] [Abstract][Full Text] [Related]
4. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis.
Cui S; Zhang Y; Liu L; Li Y; Zhou R; Huang X; Cao S; Huo X; Wang N
Ann Palliat Med; 2021 Feb; 10(2):1851-1860. PubMed ID: 33474947
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract][Full Text] [Related]
9. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
Jin Y; Lin C; Shi X; He Q; Yan J; Yu X; Chen M
BMC Cancer; 2022 May; 22(1):586. PubMed ID: 35643428
[TBL] [Abstract][Full Text] [Related]
10. Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction.
Zungsontiporn N; Ouwongprayoon P; Boonsirikamchai P; Leelayuwatanakul N; Vinayanuwattikun C; Moonai K; Khongkhaduead E; Thorner PS; Shuangshoti S; Teerapakpinyo C
Pathol Res Pract; 2024 Mar; 255():155213. PubMed ID: 38394807
[TBL] [Abstract][Full Text] [Related]
11. Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.
Sun Y; Dong Y; Liu X; Zhang Y; Bai H; Duan J; Tian Z; Yan X; Wang J; Wang Z
EBioMedicine; 2022 Sep; 83():104200. PubMed ID: 35932642
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
13. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
14. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
16. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
17. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
18. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
[TBL] [Abstract][Full Text] [Related]
19. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
Luo YH; Liu H; Wampfler JA; Tazelaar HD; Li Y; Peikert T; Liu D; Leventakos K; Chen YM; Yang Y; Chiou SH; Yang P
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2099-2114. PubMed ID: 34436667
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.
Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR
Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
